Reduced Scaling and Skin-Care Burden Following Topical Silica-Based Treatment in a Child With Harlequin Ichthyosis: A Case Report

Harlequin ichthyosis (HI) is a severe congenital disorder of keratinization caused by pathogenic variants in ABCA12 and characterized by profound epidermal barrier dysfunction, hyperkeratosis, and lifelong skin-care requirements. We describe changes in scaling and caregiver-reported treatment burden following introduction of an amorphous silica-containing topical formulation in a 16-month-old girl with genetically confirmed HI. The patient had a characteristic neonatal phenotype and had been managed with intensive topical emollient and barrier therapy without systemic retinoids. At baseline, she had generalized erythroderma and persistent hyperkeratotic scaling requiring approximately four hours of daily bathing with scale-removal care and frequent emollient application. A developmental topical emollient containing milled amorphous hydrated silica fibers was incorporated into her existing home skin-care regimen. Within days, the caregiver reported reduced scale accumulation and topical product requirements, with bathing intervals extending to approximately 36 hours. Serial photographs and contemporaneous caregiver communications documented sustained reductions in scaling over subsequent months, while erythema remained largely unchanged. An unplanned interruption in product availability was associated with increased scaling, followed by renewed improvement after treatment resumed. No serious treatment-associated adverse events were reported in the available caregiver documentation. In this uncontrolled retrospective case, use of the silica-containing topical formulation was temporally associated with reduced visible scaling and skin-care burden. The withdrawal-rechallenge pattern strengthens this temporal association but does not establish causality. These findings are hypothesis-generating and support prospective investigation of silica-containing topical formulations for HI using objective measures of scaling, epidermal barrier function, safety, and caregiver burden.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-11-16
DOI
https://doi.org/10.7759/cureus.119736
Primary Topic
Genetic and rare skin diseases.
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Reduced Scaling and Skin-Care Burden Following Topical Silica-Based Treatment in a Child With Harlequin Ichthyosis: A Case Report

Adam M. Jorgensen, Stephen Bearman, Aubrey Montebello
1 links
Cureus
Genetic and rare skin diseases.
article

Reduced Scaling and Skin-Care Burden Following Topical Silica-Based Treatment in a Child With Harlequin Ichthyosis: A Case Report

Adam M. Jorgensen, Stephen Bearman, Aubrey Montebello
article en

Abstract

Harlequin ichthyosis (HI) is a severe congenital disorder of keratinization caused by pathogenic variants in ABCA12 and characterized by profound epidermal barrier dysfunction, hyperkeratosis, and lifelong skin-care requirements. We describe changes in scaling and caregiver-reported treatment burden following introduction of an amorphous silica-containing topical formulation in a 16-month-old girl with genetically confirmed HI. The patient had a characteristic neonatal phenotype and had been managed with intensive topical emollient and barrier therapy without systemic retinoids. At baseline, she had generalized erythroderma and persistent hyperkeratotic scaling requiring approximately four hours of daily bathing with scale-removal care and frequent emollient application. A developmental topical emollient containing milled amorphous hydrated silica fibers was incorporated into her existing home skin-care regimen. Within days, the caregiver reported reduced scale accumulation and topical product requirements, with bathing intervals extending to approximately 36 hours. Serial photographs and contemporaneous caregiver communications documented sustained reductions in scaling over subsequent months, while erythema remained largely unchanged. An unplanned interruption in product availability was associated with increased scaling, followed by renewed improvement after treatment resumed. No serious treatment-associated adverse events were reported in the available caregiver documentation. In this uncontrolled retrospective case, use of the silica-containing topical formulation was temporally associated with reduced visible scaling and skin-care burden. The withdrawal-rechallenge pattern strengthens this temporal association but does not establish causality. These findings are hypothesis-generating and support prospective investigation of silica-containing topical formulations for HI using objective measures of scaling, epidermal barrier function, safety, and caregiver burden.

Cureus
Ireland Army Community Hospital (US), San Antonio Uniformed Services Health Education Consortium (US)
Good health and well-being
Genetic and rare skin diseases.
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon